|Call for proposal||H2020-MSCA-ITN-2017|
|Implementation period||01.01.2018. – 31.12.2021.|
|Project coordinator||University of Antwerp, Belgium|
|Project partners||Sorbonne Université, France|
|Latvian Institute of Organic Synthesis, Latvia|
|University of Valladolid, Spain|
|University of Eastern Finland, Finland|
|University Hospital Cologne, Germany|
|Institute of Experimental Biology and Technology, Portugal|
|Project web page||www.itded3.eu|
|Leader of Latvian team||Prof. Aigars Jirgensons|
|Total Costs||3 002 689.44 EUR|
|EU contribution||3 002 689.44 EUR|
|Costs for Latvian partner||223 577.64 EUR|
The major research objective of the IT-DED³ project is to accelerate new therapy and biomarker development in the field of the dry eye disease (DED) by creating a multidisciplinary European research and training network around DED research.
IT-DED3 will handle different therapeutic approaches for DED treatment such as synthesized and upscaled small molecules (serine protease and RIPK1 inhibitors, natural compounds) and will develop innovative drug delivery systems, which will be tested in validated and newly developed in vivo models for DED. For patient stratification, which is highly needed in the field of DED, we will identify new biomarkers and develop innovative imaging techniques in both animal models and in humans.
IT-DED3 constitutes a unique platform for a true translational research dedicated to patients suffering from DED and is able to translate basic research into patient applications (‘bench-to-bedside’ principle).